Skip to main content
William Powderly, MD, Infectious Disease, Saint Louis, MO

WilliamGerardPowderlyMD

Infectious Disease • Saint Louis, MO

HIV/AIDS Medicine, Transplant/Immunocompromised States, International Health, Travel & Tropical

Director, Institute for Public Health. Washington University

Join to view full profile

Dr. Powderly is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Powderly's full profile

Already have an account?

  • Office

    620 S Taylor Ave
    # Dv
    Saint Louis, MO 63110
    Phone+1 314-362-9098
    Fax+1 314-362-9851

Summary

  • Dr. William Powderly is an infectious disease specialist in Saint Louis, MO. He received his medical degree from University College of Dublin National Univ SOM and has been in practice 38 years. He specializes in hiv/aids medicine, transplant/immunocompromised states, and international health, travel & tropical and is experienced in public health and infectious disease. He has more than 500 publications and over 10000 citings.

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 1983 - 1986
  • University College of Dublin National Univ SOM
    University College of Dublin National Univ SOMClass of 1979, MD

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2013 - 2025
  • Royal College Of Physicians in IrelandInternal Medicine
  • Royal College of Physicians In IrelandMedicine

Publications & Presentations

PubMed

Authored Content

  • Cryptococcal Meningitis and Aids: News from IAS 2021August 2021

Press Mentions

  • WashU Medicine Celebrates First R01 Recipients
    WashU Medicine Celebrates First R01 RecipientsOctober 16th, 2024
  • Clinical and Translational Research Receives $61 Million Grant Support
    Clinical and Translational Research Receives $61 Million Grant SupportMay 12th, 2022

Grant Support

  • WU 122: Evaluate Metabolic Effects Of Discontinuation Of Antiretroviral TherapyNational Center For Research Resources2004
  • Study Of Once-Weekly Alendronate In Hiv-Infected SubjectsNational Center For Research Resources2004
  • Rosiglitazone &Exercise Training: Effects On Hiv-Infected PeopleNational Center For Research Resources2004
  • Patient Recruitment &Clinical Management CoreNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2003
  • Infectious Disease/Basic Microbial Pathogenic MechanismsNational Institute Of Allergy And Infectious Diseases1999–2003
  • Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–2003
  • T20 With Abacavir, Amprenavir And Efavirenz In HIVNational Center For Research Resources2000–2002
  • ACTG A5047:Pharmacokinetic Interactions With Protease Inhibitors &Lipid LoweringNational Center For Research Resources2000–2002
  • ACTG 400: Phase 2 Trial Of Salvage Antiretroviral Therapies For HIV InfectionNational Center For Research Resources2000–2002
  • Core--Clinical FacilityNational Institute Of Allergy And Infectious Diseases1998–2002
  • Diabetes And Lipid Disorders In HIV Infection Treated With Protease InhibitorsNational Center For Research Resources1999
  • Diabetes And Lipid Disorders In HIV Infected Treated With Protease InhibitorsNational Center For Research Resources1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--Clinical FacilityNational Institute Of Allergy And Infectious Diseases1998
  • Core--Clinical ResearchNational Institute Of Allergy And Infectious Diseases1997
  • Antiviral Efficacy Pharmacokinetic/Safety Of ABT-538 In HIV Infected PatientsNational Center For Research Resources1996
  • AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
  • Trial Of Foscarnet In AIDS Patients With CMV RetinitisNational Center For Research Resources1990
  • Secondary Prophylaxis Of Pneumocystis Pneumonia In AIDSNational Center For Research Resources1990
  • Prevention Of Pneumocystis Pneumonia In Advanced HIV InfectionNational Center For Research Resources1990
  • Phase I Study Of Sg48334 In Patients With AIDS Related ComplexNational Center For Research Resources1990

Professional Memberships

Dr. William Powderly, Dr. William Powderly, MD, Dr. W Powderly, Dr. William Gerard Powderly